Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible?

Johan Garssen; Juandy Jo; Johan Garssen; Juandy Jo

doi:10.3934/Allergy.2017.1.43

AIMS Allergy and Immunology

2017, Volume 1, Issue 1: 43-49. doi: 10.3934/Allergy.2017.1.43

Previous Article Next Article

Mini review

Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible?

Johan Garssen ^1,2,
Juandy Jo ^{1,3
,
,}

1.
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
2.
Department of Immunology, Nutricia Research, Utrecht, the Netherlands
3.
Department of Immunology, Nutricia Research, Singapore

Received: 07 June 2017 Accepted: 14 July 2017 Published: 19 July 2017

Adoptive T-cell immunotherapy is gaining credibility and popularity as a potential tool to cure cancer. Genetic engineering utilization of this therapeutic mode currently comes in the forms of chimeric antigen receptor- and T-cell receptor-engineered T cells. This short review focuses on opportunities to use engineered T cells to treat viral hepatitis-associated hepatocellular carcinoma.
- adoptive T-cell immunotherapy,
- chimeric antigen receptor,
- T-cell receptor,
- viral hepatitis,
- hepatocellular carcinoma
Citation: Johan Garssen, Juandy Jo. Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible?[J]. AIMS Allergy and Immunology, 2017, 1(1): 43-49. doi: 10.3934/Allergy.2017.1.43

Related Papers:

Abstract

Adoptive T-cell immunotherapy is gaining credibility and popularity as a potential tool to cure cancer. Genetic engineering utilization of this therapeutic mode currently comes in the forms of chimeric antigen receptor- and T-cell receptor-engineered T cells. This short review focuses on opportunities to use engineered T cells to treat viral hepatitis-associated hepatocellular carcinoma.

References

[1]	June CH, Riddell SR, Schumacher TN (2015) Adoptive cellular therapy: a race to the finish line.Sci Transl Med 7: 280–287.
[2]	Harris DT, Kranz DM (2016) Adoptive T cell therapies: a comparison of t cell receptors and chimeric antigen receptors. Trends Pharmacol Sci 37: 220–230. doi: 10.1016/j.tips.2015.11.004
[3]	Figueroa JA, Reidy A, Mirandola L, et al. (2015) Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 34: 154–187. doi: 10.3109/08830185.2015.1018419
[4]	Ramos CA, Dotti G (2011) Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Th 11: 855–873. doi: 10.1517/14712598.2011.573476
[5]	Porter DL, Levine BL, Kalos M, et al. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 365: 725–733. doi: 10.1056/NEJMoa1103849
[6]	Brentjens RJ, Davila ML, Riviere I, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
[7]	Grupp SA, Kalos M, Barrett D, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New Engl J Med 368: 1509–1518. doi: 10.1056/NEJMoa1215134
[8]	Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517–528.
[9]	Ramos CA, Heslop HE, Brenner MK (2016) CAR-T cell therapy for lymphoma. Annu Rev Med 67: 165–183. doi: 10.1146/annurev-med-051914-021702
[10]	Vigneron N (2015) Human tumor antigens and cancer immunotherapy. Biomed Res Int 2015: 948501.
[11]	Linette GP, Stadtmauer EA, Maus MV, et al. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863–871. doi: 10.1182/blood-2013-03-490565
[12]	Morgan RA, Chinnasamy N, Abatedaga DD, et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: 133–151. doi: 10.1097/CJI.0b013e3182829903
[13]	Walker A, Johnson R (2016) Commercialization of cellular immunotherapies for cancer. Biochem Soc Trans 44: 329–332. doi: 10.1042/BST20150240
[14]	Koh S, Shimasaki N, Suwanarusk R, et al. (2013) A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucl Acids 2: e114. doi: 10.1038/mtna.2013.43
[15]	Bertoletti A, Ferrari C (2016) Adaptive immunity in HBV infection. J Hepatol 64: S71–83. doi: 10.1016/j.jhep.2016.01.026
[16]	Jo J, Lohmann V, Bartenschlager R, et al. (2011) Experimental models to study the immunobiology of hepatitis C virus. J Gen Virol 92: 477–493. doi: 10.1099/vir.0.027987-0
[17]	Pasetto A, Frelin L, Aleman S, et al. (2012) TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. J Immunol 189: 4510–4519. doi: 10.4049/jimmunol.1201613
[18]	Sautto GA, Wisskirchen K, Clementi N, et al. (2016) Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 65: 512–523. doi: 10.1136/gutjnl-2014-308316
[19]	Zhang Y, Liu YY, Moxley KM, et al. (2010) Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog 6: e1001018. doi: 10.1371/journal.ppat.1001018
[20]	Balasiddaiah A, Davanian H, Aleman S, et al. (2017) Hepatitis C virus-specific T cell receptor mRNA-engineered human t cells: impact of antigen specificity on functional properties. J Virol 91: e00010–17.
[21]	Pawlotsky JM, Aghemo A, Back D (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66: 153–194. doi: 10.1016/j.jhep.2016.09.001
[22]	Krebs K (2013) T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145: 456–465. doi: 10.1053/j.gastro.2013.04.047
[23]	Gehring AJ, Xue SA, Ho ZZ, et al. (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55: 103–110. doi: 10.1016/j.jhep.2010.10.025
[24]	Banu N, Chia A, Zi ZH, et al. (2014) Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections. Sci Rep 4: 4166–4175.
[25]	Perz JF, Armstrong GL, Farrington LA, et al. (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529–538. doi: 10.1016/j.jhep.2006.05.013
[26]	Brechot C, Pourcel C, Louise A, et al. (1980) Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286: 533–535. doi: 10.1038/286533a0
[27]	Qasim W, Brunetto M, Gehring A, et al. (2015) Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 62: 486–491. doi: 10.1016/j.jhep.2014.10.001
[28]	Koh S, Tan A, Li L, et al. (2016) Targeted therapy of hepatitis B virus-related hepatocellular carcinoma: present and future. Diseases 4: 10–16. doi: 10.3390/diseases4010010
[29]	Spear TT, Callender GG, Roszkowski JJ, et al. (2016) TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immun 65: 293–304. doi: 10.1007/s00262-016-1800-2

Reader Comments

Your name:*

Email:*
© 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)